Endothelial progenitor cells in diabetic patients with myocardial infarction - Can statins improve their function?

European Journal of Pharmacology

Volumn 741, Issue , 2014, Pages 25-36

  António, Natália ^a,b   Soares, Ana ^a,c   Fernandes, Rosa ^a,c   Soares, Francisco ^b   Lopes, Ana ^d   Carvalheiro, Tiago ^d   Paiva, Artur ^d   Providência, Luís A ^b   Gonçalves, Lino ^b   Fontes Ribeiro, Carlos ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d IP   (Portugal)

Author keywords

Diabetes mellitus; Endothelial progenitor cells; Function; Myocardial infarction Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOGENESIS; CELL CULTURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; PROSPECTIVE STUDIES;

EID: 84906565744     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.07.010     Document Type: Article

References (66)

1. R.D. Abbott, R.P. Donahue, W.B. Kannel, and P.W. Wilson The impact of diabetes on survival following myocardial infarction in men vs women. The framingham study JAMA 260 1988 3456 3460
2. T. Asahara, T. Murohara, A. Sullivan, M. Silver, R. van der Zee, T. Li, B. Witzenbichler, G. Schatteman, and J.M. Isner Isolation of putative progenitor endothelial cells for angiogenesis Science 275 1997 964 967
3. B. Assmus, C. Urbich, A. Aicher, W.K. Hofmann, J. Haendeler, L. Rossig, I. Spyridopoulos, A.M. Zeiher, and S. Dimmeler HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes Circ. Res. 92 2003 1049 1055
4. M. Aviram, O. Hussein, M. Rosenblat, S. Schlezinger, T. Hayek, and S. Keidar Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy J. Cardiovasc. Pharmacol. 31 1998 39 45
5. D.M. Boudreau, O. Yu, and J. Johnson Statin use and cancer risk: a comprehensive review Expert Opin. Drug Saf. 9 2010 603 621
6. A. Ceriello Hypothesis: the "metabolic memory", the new challenge of diabetes Diabetes Res. Clin. Pract. 86 Suppl 1 2009 S2 S6
7. Y.H. Chen, S.J. Lin, F.Y. Lin, T.C. Wu, C.R. Tsao, P.H. Huang, P.L. Liu, Y.L. Chen, and J.W. Chen High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms Diabetes 56 2007 1559 1568
8. C.C. Cheng, S.J. Chang, Y.N. Chueh, T.S. Huang, P.H. Huang, S.M. Cheng, T.N. Tsai, J.W. Chen, and H.W. Wang Distinct angiogenesis roles and surface markers of early and late endothelial progenitor cells revealed by functional group analyses BMC Genomics 14 2013 182
9. W. Churdchomjan, P. Kheolamai, S. Manochantr, P. Tapanadechopone, C.Y.U.P. Tantrawatpan, and S. Issaragrisil Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control BMC Endocr. Disord. 10 2010 5
10. M. Crisby, G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, and J. Nilsson Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 2001 926 933
11. K.M. Dale, C.I. Coleman, N.N. Henyan, J. Kluger, and C.M. White Statins and cancer risk: a meta-analysis JAMA 295 2006 74 80
12. F. Deschaseaux, Z. Selmani, P.E. Falcoz, N. Mersin, N. Meneveau, A. Penfornis, C. Kleinclauss, S. Chocron, J.P. Etievent, P. Tiberghien, J.P. Kantelip, and S. Davani Two types of circulating endothelial progenitor cells in patients receiving long term therapy by HMG-CoA reductase inhibitors Eur. J. Pharmacol. 562 2007 111 118
13. S. Dimmeler, A. Aicher, M. Vasa, C. Mildner-Rihm, K. Adler, M. Tiemann, H. Rutten, S. Fichtlscherer, H. Martin, and A.M. Zeiher HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway J. Clin. Invest. 108 2001 391 397
14. S.M. Donahoe, G.C. Stewart, C.H. McCabe, S. Mohanavelu, S.A. Murphy, C.P. Cannon, and E.M. Antman Diabetes and mortality following acute coronary syndromes JAMA 298 2007 765 775
15. K. Egashira, Y. Hirooka, H. Kai, M. Sugimachi, S. Suzuki, T. Inou, and A. Takeshita Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia Circulation 89 1994 2519 2524
16. A. El-Osta, D. Brasacchio, D. Yao, A. Pocai, P.L. Jones, R.G. Roeder, M.E. Cooper, and M. Brownlee Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia J. Exp. Med. 205 2008 2409 2417
17. G.P. Fadini, M. Albiero, E. Boscaro, L. Menegazzo, A. Cabrelle, T. Piliego, M. Federici, C. Agostini, and A. Avogaro Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells Cell Biol. Int. 34 2010 709 715
18. G.P. Fadini, M. Miorin, M. Facco, S. Bonamico, I. Baesso, F. Grego, M. Menegolo, S.V. de Kreutzenberg, A. Tiengo, C. Agostini, and A. Avogaro Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus J. Am. Coll. Cardiol. 45 2005 1449 1457
19. G.P. Fadini, S. Sartore, C. Agostini, and A. Avogaro Significance of endothelial progenitor cells in subjects with diabetes Diabetes Care 30 2007 1305 1313
20. G.P. Fadini, S. Sartore, M. Albiero, I. Baesso, E. Murphy, M. Menegolo, F. Grego, S. Vigili de Kreutzenberg, A. Tiengo, C. Agostini, and A. Avogaro Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy Arterioscler. Thromb. Vasc. Biol. 26 2006 2140 2146
21. G.P. Fadini, S. Sartore, I. Baesso, M. Lenzi, C. Agostini, A. Tiengo, and A. Avogaro Endothelial progenitor cells and the diabetic paradox Diabetes Care 29 2006 714 716
22. K.A. Fox, O.H. Dabbous, R.J. Goldberg, K.S. Pieper, K.A. Eagle, F. Van de Werf, A. Avezum, S.G. Goodman, M.D. Flather, F.A. Anderson Jr., and C.B. Granger Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091
23. B. Fuhrman, L. Koren, N. Volkova, S. Keidar, T. Hayek, and M. Aviram Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes Atherosclerosis 164 2002 179 185
24. K.A. Gallagher, Z.J. Liu, M. Xiao, H. Chen, L.J. Goldstein, D.G. Buerk, A. Nedeau, S.R. Thom, and O.C. Velazquez Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha J. Clin. Invest. 117 2007 1249 1259
25. J.M. Hill, G. Zalos, J.P. Halcox, W.H. Schenke, M.A. Waclawiw, A.A. Quyyumi, and T. Finkel Circulating endothelial progenitor cells, vascular function, and cardiovascular risk N. Engl. J. Med. 348 2003 593 600
26. M. Hristov, C. Fach, C. Becker, N. Heussen, E.A. Liehn, R. Blindt, P. Hanrath, and C. Weber Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment Atherosclerosis 192 2007 413 420
27. N. Krankel, V. Adams, A. Linke, S. Gielen, S. Erbs, K. Lenk, G. Schuler, and R. Hambrecht Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells Arterioscler. Thromb. Vasc. Biol. 25 2005 698 703
28. U. Landmesser, N. Engberding, F.H. Bahlmann, A. Schaefer, A. Wiencke, A. Heineke, S. Spiekermann, D. Hilfiker-Kleiner, C. Templin, D. Kotlarz, M. Mueller, M. Fuchs, B. Hornig, H. Haller, and H. Drexler Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase Circulation 110 2004 1933 1939
29. J.C. LaRosa Pleiotropic effects of statins and their clinical significance Am. J. Cardiol. 88 2001 291 293
30. J. Llevadot, S. Murasawa, Y. Kureishi, S. Uchida, H. Masuda, A. Kawamoto, K. Walsh, J.M. Isner, and T. Asahara HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells J. Clin. Invest. 108 2001 399 405
31. L. Mandelzweig, A. Battler, V. Boyko, H. Bueno, N. Danchin, G. Filippatos, A. Gitt, D. Hasdai, Y. Hasin, J. Marrugat, F. Van de Werf, L. Wallentin, and S. Behar The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004 Eur. Heart J. 27 2006 2285 2293
32. R. Marfella, K. Esposito, F. Nappo, M. Siniscalchi, F.C. Sasso, M. Portoghese, M.P. Di Marino, A. Baldi, S. Cuzzocrea, C. Di Filippo, G. Barboso, F. Baldi, F. Rossi, M. D'Amico, and D. Giugliano Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes Diabetes 53 2004 2383 2391
33. J. Martinez-Gonzalez, B. Raposo, C. Rodriguez, and L. Badimon 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation Arterioscler. Thromb. Vasc. Biol. 21 2001 804 809
34. M. Massa, V. Rosti, M. Ferrario, R. Campanelli, I. Ramajoli, R. Rosso, G.M. De Ferrari, M. Ferlini, L. Goffredo, A. Bertoletti, C. Klersy, A. Pecci, R. Moratti, and L. Tavazzi Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction Blood 105 2005 199 206
35. R.J. Medina, C.L. O'Neill, M. Sweeney, J. Guduric-Fuchs, T.A. Gardiner, D.A. Simpson, and A.W. Stitt Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities BMC Med. Genomics 3 2010 18
36. C.R. Meier, R.G. Schlienger, M.E. Kraenzlin, B. Schlegel, and H. Jick HMG-CoA reductase inhibitors and the risk of fractures JAMA 283 2000 3205 3210
37. H. Miettinen, S. Lehto, V. Salomaa, M. Mahonen, M. Niemela, S.M. Haffner, K. Pyorala, and J. Tuomilehto Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group Diabetes Care 21 1998 69 75
38. Y. Minami, M. Satoh, C. Maesawa, Y. Takahashi, T. Tabuchi, T. Itoh, and M. Nakamura Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease Eur. J. Clin. Invest. 39 2009 359 367
39. R. Mohle, F. Bautz, S. Rafii, M.A. Moore, W. Brugger, and L. Kanz The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1 Blood 91 1998 4523 4530
40. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO multinational study of vascular disease in diabetes Diabetologia 44 Suppl 2 2001 S14 S21
41. S.A. Murphy, C.P. Cannon, S.D. Wiviott, C.H. McCabe, and E. Braunwald Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial J. Am. Coll. Cardiol. 54 2009 2358 2362
42. W. Palinski New evidence for beneficial effects of statins unrelated to lipid lowering Arterioscler. Thromb. Vasc. Biol. 21 2001 3 5
43. T.R. Pedersen, N.B. Cater, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, C. Lindahl, and M. Szarek Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial) Am. J. Cardiol. 106 2010 354 359
44. J.K. Plenge, T.L. Hernandez, K.M. Weil, P. Poirier, G.K. Grunwald, S.M. Marcovina, and R.H. Eckel Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction Circulation 106 2002 1447 1452
45. M. Satoh, Y. Minami, Y. Takahashi, T. Tabuchi, T. Itoh, and M. Nakamura Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease Clin. Sci. (Lond.) 116 2009 827 835
46. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, D. Waters, A. Zeiher, B.R. Chaitman, S. Leslie, and T. Stern Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
47. S. Shintani, T. Murohara, H. Ikeda, T. Ueno, T. Honma, A. Katoh, K. Sasaki, T. Shimada, Y. Oike, and T. Imaizumi Mobilization of endothelial progenitor cells in patients with acute myocardial infarction Circulation 103 2001 2776 2779
48. D.P. Sieveking, A. Buckle, D.S. Celermajer, and M.K. Ng Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay J. Am. Coll. Cardiol. 51 2008 660 668
49. P.G. Steg, S.K. James, D. Atar, L.P. Badano, C. Blomstrom-Lundqvist, M.A. Borger, C. Di Mario, K. Dickstein, G. Ducrocq, F. Fernandez-Aviles, A.H. Gershlick, P. Giannuzzi, S. Halvorsen, K. Huber, P. Juni, A. Kastrati, J. Knuuti, M.J. Lenzen, K.W. Mahaffey, M. Valgimigli, A. van 't Hof, P. Widimsky, and D. Zahger ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J. 33 2012 2569 2619
50. T. Takahashi, C. Kalka, H. Masuda, D. Chen, M. Silver, M. Kearney, M. Magner, J.M. Isner, and T. Asahara Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization Nat. Med. 5 1999 434 438
51. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors Arterioscler. Thromb. Vasc. Biol. 21 2001 1712 1719
52. M. Takemoto, K. Node, H. Nakagami, Y. Liao, M. Grimm, Y. Takemoto, M. Kitakaze, and J.K. Liao Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J. Clin. Invest. 108 2001 1429 1437
53. O.M. Tepper, R.D. Galiano, J.M. Capla, C. Kalka, P.J. Gagne, G.R. Jacobowitz, J.P. Levine, and G.C. Gurtner Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures Circulation 106 2002 2781 2786
54. F. Timmermans, F. Van Hauwermeiren, M. De Smedt, R. Raedt, F. Plasschaert, M.L. De Buyzere, T.C. Gillebert, J. Plum, and B. Vandekerckhove Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors Arterioscler. Thromb. Vasc. Biol. 27 2007 1572 1579
55. A. Undas, K.E. Brummel, J. Musial, K.G. Mann, and A. Szczeklik Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation Circulation 103 2001 2248 2253
56. M. Vasa, S. Fichtlscherer, K. Adler, A. Aicher, H. Martin, A.M. Zeiher, and S. Dimmeler Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease Circulation 103 2001 2885 2890
57. T. Vollmer, L. Key, V. Durkalski, W. Tyor, J. Corboy, S. Markovic-Plese, J. Preiningerova, M. Rizzo, and I. Singh Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 2004 1607 1608
58. D.H. Walter, J. Haendeler, J. Reinhold, U. Rochwalsky, F. Seeger, J. Honold, J. Hoffmann, C. Urbich, R. Lehmann, F. Arenzana-Seisdesdos, A. Aicher, C. Heeschen, S. Fichtlscherer, A.M. Zeiher, and S. Dimmeler Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease Circ. Res. 97 2005 1142 1151
59. D.H. Walter, K. Rittig, F.H. Bahlmann, R. Kirchmair, M. Silver, T. Murayama, H. Nishimura, D.W. Losordo, T. Asahara, and J.M. Isner Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells Circulation 105 2002 3017 3024
60. N. Werner, S. Kosiol, T. Schiegl, P. Ahlers, K. Walenta, A. Link, M. Bohm, and G. Nickenig Circulating endothelial progenitor cells and cardiovascular outcomes N. Engl. J. Med. 353 2005 999 1007
61. P. Widimsky, W. Wijns, J. Fajadet, M. de Belder, J. Knot, L. Aaberge, G. Andrikopoulos, J.A. Baz, A. Betriu, M. Claeys, N. Danchin, S. Djambazov, P. Erne, J. Hartikainen, K. Huber, P. Kala, M. Klinceva, S.D. Kristensen, P. Ludman, J.M. Ferre, B. Merkely, D. Milicic, J. Morais, M. Noc, G. Opolski, M. Ostojic, D. Radovanovic, S. De Servi, U. Stenestrand, M. Studencan, M. Tubaro, Z. Vasiljevic, F. Weidinger, A. Witkowski, and U. Zeymer Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries Eur. Heart J. 31 2010 943 957
62. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch. Neurol. 57 2000 1439 1443
63. W.W. Wong, J. Dimitroulakos, M.D. Minden, and L.Z. Penn HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis Leukemia 16 2002 508 519
64. J. Yamaguchi, K.F. Kusano, O. Masuo, A. Kawamoto, M. Silver, S. Murasawa, M. Bosch-Marce, H. Masuda, D.W. Losordo, J.M. Isner, and T. Asahara Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization Circulation 107 2003 1322 1328
65. M.C. Yoder, L.E. Mead, D. Prater, T.R. Krier, K.N. Mroueh, F. Li, R. Krasich, C.J. Temm, J.T. Prchal, and D.A. Ingram Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals Blood 109 2007 1801 1809
66. T. Ziegelhoeffer, B. Fernandez, S. Kostin, M. Heil, R. Voswinckel, A. Helisch, and W. Schaper Bone marrow-derived cells do not incorporate into the adult growing vasculature Circ. Res. 94 2004 230 238